AI assistant
SELLAS Life Sciences Group, Inc. — Director's Dealing 2022
Feb 1, 2022
33651_dirs_2022-02-01_ab8974e9-7e00-4e20-8015-eb00c8cd188f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2022-01-31
Reporting Person: VAN NOSTRAND ROBERT L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-31 | Common Stock | A | 1900 | $0.00 | Acquired | 1900 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-31 | Stock Option (Right to Buy) | $5.34 | A | 7125 | Acquired | 2032-01-31 | Common Stock (7125) | Direct |
Footnotes
F1: The Reporting Person received an award of 1,900 restricted stock units on January 31, 2022, which shall vest in full on December 1, 2022, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
F2: The shares subject to the option will fully vest on the earlier of (x) January 31, 2023 (the first anniversary of the date of grant) or (y) the business day prior to the 2023 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.